Editor-in-Chief

Amedeo Lonardo
Operating Unit of Metabolic Syndrome, Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara, Modena, Italy.
HomePage
Bio
Born in 1957, graduated in Medicine summa cum laude, specialist in Gastroenterology & Digestive Endoscopy; Pediatrics and Internal Medicine. Qualified fit as Full Professor in Gastroenterology and Associate Professor in Internal Medicine at the Italian National University Examination (2017). Author of 205 published papers, H-index 52 (source Scopus, accessed in April 2021), Dr Lonardo has completed more than 700 certified Reviews for international journals of Gastroenterology, Hepatology, Metabolism and Internal Medicine. In 2021, Dr. Lonardo has been recognized by Expertscape as “World Expert in Fatty Liver” and placed in the top 0.012% of scholars writing about “fatty liver” in the world over the past 10 years (< a href="https://www.expertscape.com/ex/fatty+liver" target="_blank">https://www.expertscape.com/ex/fatty+liver). His research interests include: MAFLD; primary NAFLD and NAFLD secondary to endocrine disorders; sex differences in NAFLD; bi-directional associations of metabolic syndrome and NAFLD; liver and hypobetalipoproteinemia; dysmetabolism in HCV infection; diabetes in cirrhosis. On these topics, he has delivered several lectures before International and Italian Congresses. He is presently a tutor for fellows in Internal Medicine at the University of Modena and Reggio Emilia.
Research Interests
MAFLD, NAFLD, endocrine disorders, sex differences in NAFLD, metabolic syndrome, liver, hypobetalipoproteinemia, dysmetabolism in HCV infection, diabetes in cirrhosis
Contributions:

Editorial: Metabolism and Target Organ Damage

Precision medicine approaches in metabolic disorders and target organ damage: where are we now, and where are we going?

Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies

The Fatty liver Index (FLI) 15 years later: a reappraisal

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Commentary: Of women, liver, and heart

Concise review: Breastfeeding, lactation, and NAFLD. An updated view of cross-generational disease transmission and prevention

Is liver fibrosis a risk factor for gynecological cancers?

Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Could controversies in the arena of fatty liver disease be a potential gate for the democratization of science?

Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Special Issue:

Organ Dysfunction in Metabolic-Associated Fatty Liver Disease: Effect of Cofactors

Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Metabolism and Target Organ Damage
ISSN 2769-6375 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/